June 23, 2025
| Today’s news and insights for biopharma leaders
While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s version of psilocybin could be as a depression treatment.
|
The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo resolved its shortage.
|
Company shares doubled on Phase 2 study results suggesting its drug could become an alternative to vaccines for flu prevention.
|
Study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of research overnight. Explore how a new class of drugs could mark the future of immunotherapy in
|
Illumina expects that adding SomaLogic will aid its “multiomics” business strategy and strengthen the value of its gene sequencing products.
|
A dramatic pullback in public biotech investment catalyzed by economic and regulatory upheaval is putting even more stress on startups navigating a yearslong downturn.
|
|
In today’s competitive pharmaceutical market, creative omnichannel campaigns help brands stand out amid complex regulations. Discover how to innovate strategies to drive growth in this playbook.
|
|
From Our Library
Infographic
Custom content for UBC
|
Playbook
Custom content for WCG
|
Playbook
Custom content for Medrio
|
| 
